Mohammad Shahrokh Esfahani

Mohammad Shahrokh Esfahani

Auto-generated profile, based on publicly available information

Mohammad Shahrokh Esfahani

Stanford University 6 Department of Medicine, Divisions of Oncology and Hematology Stanford, California

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2025 in Cancer Discovery
Verified
Journal Article
Closed access
EMEverett J. Moding
Everett J. Moding
MEMohammad Shahrokh Esfahani
Mohammad Shahrokh Esfahani
CJCheng Jin
Cheng Jin
AHAngela B. Hui
Angela B. Hui
BNBarzin Y. Nabet
Barzin Y. Nabet
MDMaximilian Diehn
Maximilian Diehn
The complementarity and clinical utility of combining liquid biopsies and radiomic image analysis has not been demonstrated. ctDNA minimal residual disease after chemoradiotherapy (CRT) for non–small cell lung cancer (NSCLC) is highly prognostic, but on-treatment biomarkers are needed to enable response-adapted therapies. In this study, we analyzed 418 patients with NSCLC undergoing CRT to develop and validate a novel dynamic risk model that accurately predicts ultimate progression-free survival during treatment. We optimize tissue-free variant calling from plasma samples to facilitate ctDNA monitoring and demonstrate the importance of accounting for persistent clonal hematopoiesis variants. We show that mid-CRT ctDNA concentration is prognostic for disease progression and integrate additional pre-CRT risk factors, including radiomics, into a combined model that improves outcome prediction. Our results suggest that tumor features, radiomics, and mid-CRT ctDNA analysis are complementary and can identify patients at high and low risk of progression to potentially enable response-adapted therapies. Significance: This study demonstrates that combining tumor features, radiomics, and ctDNA analysis improves outcome prediction in NSCLC treated with CRT therapy. Our integrated model could enable personalized and response-adapted therapies to reduce toxicity and improve outcomes in patients.

30 January 2026 in Cancer Discovery
Verified
Journal Article
Closed access
TATomohiro Aoki
Tomohiro Aoki
GDGerben Duns
Gerben Duns
SRShinya Rai
Shinya Rai
AJAixiang Jiang
Aixiang Jiang
ALAndrew Lytle
Andrew Lytle
CSChristian Steidl
Christian Steidl
The tissue architecture of classic Hodgkin lymphoma (cHL) is unique among cancers and is characterized by rare malignant Hodgkin and Reed–Sternberg cells that coevolve with a complex ecosystem of immune cells in the tumor microenvironment (TME). The lack of a comprehensive systems-level interrogation has hindered the description of disease heterogeneity and clinically relevant molecular subtypes. In this study, we employed an integrative, multimodal approach to characterize cHL tumors using malignant cell sequencing, spatial transcriptomics, and imaging mass cytometry. We identified four molecular subtypes (CST, CN913, STB, and CN2P), each characterized by distinct clinical features, mutational patterns, malignant cell gene expression profiles, and spatial architecture involving immune cell populations. Functional modeling of CSF2RB mutations, a characteristic feature of the CST subtype, revealed dysregulated oncogenic signaling and unique TME cross-talk. These findings highlight the significance of multidimensional profiling in elucidating patterns of molecular alterations that drive immune ecosystems and underlie therapeutically exploitable vulnerabilities. Significance: Our systematic and comprehensive genomic and spatially resolved profiling of Hodgkin lymphoma revealed a paradigmatic link between a genetic disease subtype and TME composition and function. Insights into mutation-driven mechanisms of deregulated cytokine signaling will pave the way for therapeutic interventions that interfere with oncogenic signaling and cellular ecosystems in cancer.

2 October 2026 in Nature Medicine
Verified
Journal Article
Open access
PDF file
KLKevin J. Liu
Kevin J. Liu
WSWilliam Y. Shi
William Y. Shi
MNMonica C. Nesselbush
Monica C. Nesselbush
NPNick A. Phillips
Nick A. Phillips
KMKathleen E. Mach
Kathleen E. Mach
MDMaximilian Diehn
Maximilian Diehn
Urine biomarkers promise to improve noninvasive detection and molecular characterization of genitourinary malignancies. Here we describe urine random priming and affinity capture of cell-free RNA (cfRNA) fragments for enrichment analysis by sequencing (uRARE-seq), a liquid biopsy method for urine cfRNA profiling, and apply it to 683 urine samples from patients with cancer and controls. Urine cfRNA contained transcripts from genitourinary tissues and, in patients with prostate, kidney or bladder cancer, tumor-derived transcripts. uRARE-seq demonstrated 95% sensitivity at 90% specificity for detecting localized bladder cancer. The method outperformed urine tumor DNA analysis and was unaffected by the presence of field-effect mutations. Urine cfRNA analysis also sensitively detected minimal residual disease and distinguished complete molecular responses after surgery from those after intravesical Bacillus Calmette–Guérin (BCG). Pretreatment urine from complete responders to BCG was enriched for T cell and other immune signatures, suggesting a preexisting antitumor immune response, whereas nonresponders showed higher expression of proliferation-related genes. In pretreatment urine from 114 patients, this biological difference enabled development of a biomarker predicting likelihood of response to BCG versus chemotherapy (area under the curve 0.93) that was strongly associated with risk of recurrence. Urine cfRNA analysis is therefore a promising biomarker approach for bladder cancer and potentially other urologic malignancies, although prospective studies are needed to assess its clinical utility.

17 June 2026
Verified
Other
Open access
TATomohiro Aoki
Tomohiro Aoki
GDGerben Duns
Gerben Duns
SRShinya Rai
Shinya Rai
AJAixiang Jiang
Aixiang Jiang
ALAndrew Lytle
Andrew Lytle
CSChristian Steidl
Christian Steidl
Figure S1. Co-occurrence of mutation in CHL. Figure S2. STAT6 copy number gain. Figure S3. Frequent mutations according to key clinical features. Figure S4. Copy number alterations according to EB Virus (EBV) status on HRS cells. Figure S5. Multivariable analyses on thymic mutation. Figure S6. Coding mutation count according to key clinical features in CHL. Figure S7. Impact of molecular profile on survival in CHL. Figure S8. STAT6 mutations in CHL. Figure S9. Impact of molecular profile on survival in elderly CHL. Figure S10. MHC status on HRS cells and their molecular correlates. Figure S11. Molecular Subgroups of CHL. Figure S12. Correlation between molecular subtypes and key clinical features. Figure S13. Molecular subtype and progression free survival (PFS) in Hodgkin lymphoma. Figure S14. Overview of the imaging mass cytometry (IMC) analysis and panel. Figure S15. Spatial tumor-microenvironment correlates with molecular subtype in CHL. Figure S16. Membrane map depicting major immune cell populations in each molecular subgroup. Figure S17. Correlation between molecular subtypes and key features. Figure S18. Evidence of CSF2RB mutant allele expression at the protein level in L-1236 KO model. Figure S19. CSF2RB mutations confer cytokine-dependent gain-of-function signaling in the L-428 model. Figure S20. CSF2RB mutations promote activation of the STAT5 signaling pathway. Figure S21. Co-expression of CSF2RB-WT and E788* mutant enhances downstream cytokine responses. Figure S22. Characterization of extrinsic phenotypes of CSF2RB mutations. Figure S23. Tumor-microenvironment characterization with molecular subtype in CHL. Figure S24. Cohort and study design overview for the HLGen development. Figure S25. Oncoplot of the CHL samples from Stanford ctDNA cohort (n = 293), with clinical annotation according to molecular subtype. Figure S26. Impact of feature list reduction on HLGen classifier performance. Figure S27. Graphical summary of molecular subtypes and their clinical and tumor-microenvironment ecosystem correlates in classic Hodgkin lymphoma. Figure S28. GeoMx analyses on CD30+ HRS cells. Figure S29. Segmentation on Imaging Mass Cytometry. Figure S30. Gating Strategy of regulatory T cell population.

3 April 2023
Verified
Other
Open access
JDJonathan C. Dudley
Jonathan C. Dudley
JSJoseph Schroers-Martin
Joseph Schroers-Martin
DLDaniel V. Lazzareschi
Daniel V. Lazzareschi
WSWilliam Y. Shi
William Y. Shi
SCSimon B. Chen
Simon B. Chen
MDMaximilian Diehn
Maximilian Diehn

3 April 2023
Verified
Other
Open access
JDJonathan C. Dudley
Jonathan C. Dudley
JSJoseph Schroers-Martin
Joseph Schroers-Martin
DLDaniel V. Lazzareschi
Daniel V. Lazzareschi
WSWilliam Y. Shi
William Y. Shi
SCSimon B. Chen
Simon B. Chen
MDMaximilian Diehn
Maximilian Diehn